TW200720274A - Dna-pk inhibitors - Google Patents

Dna-pk inhibitors

Info

Publication number
TW200720274A
TW200720274A TW095113561A TW95113561A TW200720274A TW 200720274 A TW200720274 A TW 200720274A TW 095113561 A TW095113561 A TW 095113561A TW 95113561 A TW95113561 A TW 95113561A TW 200720274 A TW200720274 A TW 200720274A
Authority
TW
Taiwan
Prior art keywords
dna
inhibitors
iii
compounds
formula
Prior art date
Application number
TW095113561A
Other languages
English (en)
Chinese (zh)
Inventor
Graeme Cameron Murray Smith
Niall Morrison Barr Martin
Keith Allan Menear
Marc Geoffrey Hummersone
Xiao-Ling Cockcroft
Mark Frigerio
Roger John Griffin
Bernard Thomas Golding
Ian Robert Hardcastle
David Richard Newell
Hilary Alan Calvert
Nicola Jane Curtin
Kappusamy Saravanan
Murr Marine Desage-El
Original Assignee
Kudos Pharm Ltd
Cancer Rec Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0507831A external-priority patent/GB0507831D0/en
Application filed by Kudos Pharm Ltd, Cancer Rec Tech Ltd filed Critical Kudos Pharm Ltd
Publication of TW200720274A publication Critical patent/TW200720274A/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
  • Pyrane Compounds (AREA)
TW095113561A 2005-04-15 2006-04-14 Dna-pk inhibitors TW200720274A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US67188605P 2005-04-15 2005-04-15
US67183005P 2005-04-15 2005-04-15
GB0507831A GB0507831D0 (en) 2005-04-18 2005-04-18 DNA-PK inhibitors
US69606405P 2005-07-01 2005-07-01
US71890405P 2005-09-20 2005-09-20

Publications (1)

Publication Number Publication Date
TW200720274A true TW200720274A (en) 2007-06-01

Family

ID=36579227

Family Applications (2)

Application Number Title Priority Date Filing Date
TW095113561A TW200720274A (en) 2005-04-15 2006-04-14 Dna-pk inhibitors
TW095113560A TW200720271A (en) 2005-04-15 2006-04-14 DNA-PK inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW095113560A TW200720271A (en) 2005-04-15 2006-04-14 DNA-PK inhibitors

Country Status (13)

Country Link
US (2) US20060264623A1 (OSRAM)
EP (2) EP1869040A1 (OSRAM)
JP (2) JP2008535902A (OSRAM)
KR (1) KR20080002963A (OSRAM)
AR (2) AR054438A1 (OSRAM)
AU (1) AU2006235731A1 (OSRAM)
CA (1) CA2603637A1 (OSRAM)
IL (1) IL186445A0 (OSRAM)
MX (1) MX2007012696A (OSRAM)
NO (1) NO20075809L (OSRAM)
TW (2) TW200720274A (OSRAM)
UY (1) UY29479A1 (OSRAM)
WO (2) WO2006109081A1 (OSRAM)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0119865D0 (en) * 2001-08-14 2001-10-10 Cancer Res Campaign Tech DNA-PK inhibitors
US7429660B2 (en) * 2003-08-13 2008-09-30 Kudos Pharmaceuticals Limited ATM inhibitors
KR20070059156A (ko) * 2004-09-20 2007-06-11 쿠도스 파마슈티칼스 리미티드 Dna-pk 억제제
WO2006085067A1 (en) * 2005-02-09 2006-08-17 Kudos Pharmaceuticals Limited Atm inhibitors
AR054438A1 (es) * 2005-04-15 2007-06-27 Kudos Pharm Ltd Inhibidores de adn -pk
UY31232A1 (es) * 2007-07-19 2009-03-02 Compuestos derivados de dibenzotifenilamino-cromen-4-onas activas sustituidas y sus isomeros y aplicaciones
EP2198710A1 (de) 2008-12-19 2010-06-23 Bayer CropScience AG Verwendung von 5-Pyridin-4yl-(1,3)Thiazole zur Bekämpfung phytopathogener Pilze
WO2010136778A1 (en) * 2009-05-29 2010-12-02 Kudos Pharmaceuticals Limited Dibenzothiophene derivatives as dna- pk inhibitors
WO2011001114A1 (fr) 2009-07-02 2011-01-06 Sanofi-Aventis Nouveaux derives de (6-oxo-1,6-dihydro-pyrimidin-2-yl)-amide, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
RU2561130C2 (ru) * 2009-07-02 2015-08-20 Санофи НОВЫЕ ПРОИЗВОДНЫЕ 1,2,3,4-ТЕТРАГИДРОПИРИМИДО{1,2-a}ПИРИМИДИН-6-ОНА, ИХ ПОЛУЧЕНИЕ И ФАРМАЦЕВТИЧЕСКОЕ ПРИМЕНЕНИЕ
FR2947551B1 (fr) * 2009-07-02 2012-05-18 Sanofi Aventis Nouveaux derives de 1,2,3,4-tetrahydro-pyrimido{1,2-a)pyrimidin-6-one, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt (pkb)
FR2951170B1 (fr) * 2009-10-09 2011-12-02 Sanofi Aventis Nouveaux derives de 1h-pyrimidin-2-one, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
FR2947548B1 (fr) * 2009-07-02 2012-05-18 Sanofi Aventis Nouveaux derives de 1h-pyrimidin-2-one, leur preparation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
JP5663571B2 (ja) 2009-07-02 2015-02-04 サノフイ 新規2,3−ジヒドロ−1H−イミダゾ{1,2−a}ピリミジン−5−オン誘導体、これらの調製およびこれらの薬学的使用
EP2448932B1 (fr) 2009-07-02 2014-03-05 Sanofi Nouveaux derives de 6-morpholin-4-yl-pyrimidin-4-(3h)-one, leur preparation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
FR2947550B1 (fr) * 2009-07-02 2012-05-18 Sanofi Aventis Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt (pkb)
US8399460B2 (en) * 2009-10-27 2013-03-19 Astrazeneca Ab Chromenone derivatives
CN102858528B (zh) 2010-04-15 2016-05-11 3M创新有限公司 包括光学活性区域和光学非活性区域的回射制品
US20130109687A1 (en) * 2010-04-30 2013-05-02 Gary J. Nabel Methods of treating hiv infection: inhibition of dna dependent protein kinase
DE102010035744A1 (de) * 2010-08-28 2012-03-01 Merck Patent Gmbh Imidazolonylchinoline
HUE024504T2 (en) 2010-12-23 2016-01-28 Sanofi Sa Pyrimidine derivatives, a process for their preparation and their use in medicine
PL2658844T3 (pl) 2010-12-28 2017-04-28 Sanofi Nowe pochodne pirymidyn, ich wytwarzanie i ich zastosowanie farmaceutyczne jako inhibitorów fosforylacji AKT(pkb)
US8530470B2 (en) * 2011-04-13 2013-09-10 Astrazeneca Ab Chromenone derivatives
HUE054031T2 (hu) 2012-04-24 2021-08-30 Vertex Pharma DNS-PK inhibitorok
ES2637829T3 (es) * 2012-06-15 2017-10-17 Basf Se Cristales multicomponentes que comprenden dasatinib y agentes de formación de cocristales seleccionados
FR2992316A1 (fr) 2012-06-22 2013-12-27 Sanofi Sa Derives de pyrimidinones, leur preparation et leur application en therapeutique
FR2992314B1 (fr) 2012-06-22 2015-10-16 Sanofi Sa Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one comportant une morpholine substituee, leur preparation et leur utilisation pharmaceutique
RU2676259C2 (ru) 2013-03-12 2018-12-27 Вертекс Фармасьютикалз Инкорпорейтед Ингибиторы днк-пк
JP6784942B2 (ja) * 2014-12-02 2020-11-18 オールテリティ セラピューティクス リミテッド 4H−ピリド[1,2−a]ピリミジン−4−オン化合物
AU2017335648B2 (en) 2016-09-27 2022-02-17 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors
CN109232476B (zh) * 2018-11-06 2020-06-26 常州大学 一种制备n-苯基-3-吗啡啉丙酰胺的方法
US20230111712A1 (en) * 2020-03-13 2023-04-13 Arizona Board Of Regents On Behalf Of The University Of Arizona Stable reactive compositions for bioconjugation, probes, and protein labeling
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1303724A (OSRAM) 1969-05-14 1973-01-17
JPH0753725B2 (ja) 1987-10-08 1995-06-07 富山化学工業株式会社 4h―1―ベンゾピラン―4―オン誘導体およびその塩、それらの製造法並びにそれらを含有する抗炎症剤
US5284856A (en) * 1988-10-28 1994-02-08 Hoechst Aktiengesellschaft Oncogene-encoded kinases inhibition using 4-H-1-benzopyran-4-one derivatives
JPH04502322A (ja) 1988-12-21 1992-04-23 ジ・アップジョン・カンパニー 抗アテローム性動脈硬化症性および抗血栓性1―ベンゾピラン―4―オン類および2―アミノ―1,3―ベンゾオキサジン―4―オン類
US5703075A (en) * 1988-12-21 1997-12-30 Pharmacia & Upjohn Company Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
JPH03215423A (ja) 1990-01-18 1991-09-20 Kyowa Hakko Kogyo Co Ltd 血管拡張剤
CA2081577A1 (en) 1990-06-20 1991-12-21 Ronald B. Gammill Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1, 3-benzoxazine-4-ones
US5252735A (en) 1990-06-29 1993-10-12 The Upjohn Company Antiatherosclerotic and antithrombotic 2-amino-6-phenyl-4H-pyran-4-ones
US5302613A (en) 1990-06-29 1994-04-12 The Upjohn Company Antiatheroscleroic and antithrombotic 2-amino-6-phenyl-4H-pyran-4-ones
DK0489877T3 (da) 1990-06-29 1996-02-05 Upjohn Co Antiatherosklerotiske og antithrombotiske 2-amino-6-phenyl-4H-pyran-4-oner
WO1994005283A1 (fr) 1992-09-02 1994-03-17 Kyowa Hakko Kogyo Co., Ltd. Medicament anti-vih
CA2159192C (en) * 1993-04-09 2006-07-25 Keiichi Tanaka Immunomodulator cell adhesion inhibitor, and agent for treating and preventing autoimmune diseases
US5378725A (en) 1993-07-19 1995-01-03 The Arizona Board Of Regents Inhibition of phosphatidylinositol 3-kinase with wortmannin and analogs thereof
US5441947A (en) 1993-08-25 1995-08-15 Eli Lilly And Company Methods of inhibiting vascular restenosis
US5468773A (en) 1993-08-25 1995-11-21 Eli Lilly And Company Methods for inhibiting bone loss and cartilage degradation using wortmannin and its analogs
US5504103A (en) 1993-08-25 1996-04-02 Eli Lilly And Company Inhibition of phosphatidylinositol 3-kinase with 17 β-hydroxywortmannin and analogs thereof
CA2133815A1 (en) 1993-10-12 1995-04-13 Jeffrey Alan Dodge Inhibition of phosphatidylinositol 3-kinase with viridin, demethoxyviridin, viridiol, demethoxyviridiol, virone, wortmannolone, and analogs thereof
US6632789B1 (en) 1994-04-29 2003-10-14 The United States Of America As Represented By The Secretary Of The Navy Methods for modulating T cell responses by manipulating intracellular signal transduction
US5480906A (en) 1994-07-01 1996-01-02 Eli Lilly And Company Stereochemical Wortmannin derivatives
GB9521987D0 (en) 1995-10-26 1996-01-03 Ludwig Inst Cancer Res Phosphoinositide 3-kinase modulators
US5733920A (en) * 1995-10-31 1998-03-31 Mitotix, Inc. Inhibitors of cyclin dependent kinases
AU1461197A (en) 1995-11-16 1997-06-05 Icos Corporation Cell cycle checkpoint pik-related kinase materials and methods
GB2302021A (en) 1996-10-16 1997-01-08 Lilly Co Eli Inhibiting bone loss or resorption
CA2292540A1 (en) 1997-06-06 1998-12-10 Jann N. Sarkaria Screening for phosphatidylinositol related-kinase inhibitors
AU8068198A (en) 1997-06-13 1998-12-30 President And Fellows Of Harvard College Methods for treating human cancers
FR2776291B1 (fr) 1998-03-18 2000-06-16 Pf Medicament Nouveaux derives bis-benzamides, leur procede de fabrication, les compositions pharmaceutiques les contenant et leur utilisation comme medicament
US6387640B1 (en) * 1999-02-10 2002-05-14 St. Jude Children's Research Hospital ATM kinase modulation for screening and therapies
US6348311B1 (en) 1999-02-10 2002-02-19 St. Jude Childre's Research Hospital ATM kinase modulation for screening and therapies
US6333180B1 (en) * 1999-12-21 2001-12-25 International Flavors & Fragrances Inc. Bioprocess for the high-yield production of food flavor-acceptable jasmonic acid and methyl jasmonate
AU2001230426C1 (en) * 2000-01-24 2006-06-22 Astrazeneca Ab Therapeutic morpholino-substituted compounds
EP1299101A4 (en) * 2000-06-28 2004-06-16 Teva Pharma CARVEDILOL
EP1351946A2 (en) 2000-09-01 2003-10-15 Icos Corporation Materials and methods to potentiate cancer treatment
EP1353693B1 (en) 2001-01-16 2005-03-16 Glaxo Group Limited Pharmaceutical combination containing a 4-quinazolineamine and paclitaxel, carboplatin or vinorelbine for the treatment of cancer
GB0119863D0 (en) 2001-08-14 2001-10-10 Cancer Res Campaign Tech DNA-PK inhibitors
GB0119865D0 (en) * 2001-08-14 2001-10-10 Cancer Res Campaign Tech DNA-PK inhibitors
US6908932B2 (en) 2001-10-24 2005-06-21 Iconix Pharmaceuticals, Inc. Modulators of phosphoinositide 3-kinase
AU2002357667A1 (en) 2001-10-24 2003-05-06 Iconix Pharmaceuticals, Inc. Modulators of phosphoinositide 3-kinase
US7049313B2 (en) 2002-02-25 2006-05-23 Kudos Pharmaceuticals Ltd. ATM inhibitors
NZ534821A (en) 2002-02-25 2006-07-28 Kudos Pharm Ltd Pyranones useful as ATM inhibitors
WO2003093261A1 (en) 2002-04-30 2003-11-13 Kudos Pharmaceuticals Limited Phthalazinone derivatives
US7429660B2 (en) 2003-08-13 2008-09-30 Kudos Pharmaceuticals Limited ATM inhibitors
KR20070059156A (ko) * 2004-09-20 2007-06-11 쿠도스 파마슈티칼스 리미티드 Dna-pk 억제제
WO2006085067A1 (en) 2005-02-09 2006-08-17 Kudos Pharmaceuticals Limited Atm inhibitors
AR054438A1 (es) 2005-04-15 2007-06-27 Kudos Pharm Ltd Inhibidores de adn -pk
UY31232A1 (es) 2007-07-19 2009-03-02 Compuestos derivados de dibenzotifenilamino-cromen-4-onas activas sustituidas y sus isomeros y aplicaciones

Also Published As

Publication number Publication date
CA2603637A1 (en) 2006-10-19
MX2007012696A (es) 2008-03-14
WO2006109084A1 (en) 2006-10-19
JP2008535902A (ja) 2008-09-04
UY29479A1 (es) 2006-11-30
AR053358A1 (es) 2007-05-02
IL186445A0 (en) 2008-01-20
EP1869021A1 (en) 2007-12-26
US7696203B2 (en) 2010-04-13
TW200720271A (en) 2007-06-01
US20060264427A1 (en) 2006-11-23
AR054438A1 (es) 2007-06-27
US20060264623A1 (en) 2006-11-23
KR20080002963A (ko) 2008-01-04
EP1869040A1 (en) 2007-12-26
AU2006235731A1 (en) 2006-10-19
NO20075809L (no) 2007-12-27
JP2008535903A (ja) 2008-09-04
WO2006109081A1 (en) 2006-10-19

Similar Documents

Publication Publication Date Title
TW200720274A (en) Dna-pk inhibitors
TW200634018A (en) Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and uses
GEP20094785B (en) Pyrrolopyrazoles, potent kinase inhibitors
TW200611898A (en) Organic compounds
TW201129553A (en) Dipeptidyl peptidase inhibitors
TW200616623A (en) Organic compounds
TW200716636A (en) Heterocyclic spiro-compounds
IL185275A0 (en) N-sulphonylpyrrole derivatives and pharmaceutical compositions containing the same
ATE479687T1 (de) Kinaseinhibitoren
TW200626610A (en) Analogs of 17-hydroxywortmannin as PI3K inhibitors
UA94129C2 (ru) Соединения для ингибирования митоза
BRPI0413973A (pt) compostos
WO2005087724A3 (en) Sulphonylpyrroles as hdac inhibitors
NO20070608L (no) Anvendelse av 2-tio-3,5-dicyano-4-fenyl-6-aminopyridiner ved behandling av kvalme og oppkast
TW200745028A (en) Novel sulphonylpyrroles
TW200608978A (en) Organic compounds
TW200716634A (en) Heterocyclic spiro-compounds
TW200716105A (en) Imidazole compounds
TW200624426A (en) BACE inhibitors
TW200611897A (en) Organic compounds
IN2012DN02609A (OSRAM)
TW200745027A (en) Novel sulphonylpyrroles
TW200716622A (en) Substituted piperidines
GEP20104941B (en) Pyrrolopyridine-based inhibitors of dipeptidyl peptidase iv and methods
TW200613308A (en) Cyclobutanetetracarboxylate compound and preparation method thereof